TORONTO, April 6, 2010 /PRNewswire/ -- Clearstone Central Laboratories, a leading global provider of clinical laboratory and centralized cardiac services for clinical trials, today announced the appointment of Rose Buot as Vice President of Global Quality Assurance. She will report directly to Clearstone CEO Lewis Cameron and work from the company's Baillet-en-France laboratory, near Paris, France.

Ms. Buot has a pharmaceutical engineering background with more than 13 years of Quality Assurance experience in the pre-clinical, clinical and pharmaceutical manufacturing sectors. She is well versed in international regulatory requirements pertaining to Good Clinical Practice and has a proven track record in the successful implementation and validation of quality systems.

We welcome Rose at an exciting and important time in the development of our company, said Clearstone CEO Lewis Cameron. Quality Assurance is a top priority for us and Rose's knowledge, experience and focused approach will provide expert leadership to our QA and continuous improvement programs around the world. Rose's appointment completes the establishment of a management team at Clearstone of the highest caliber following the purchase from MDS in November last year, and we look to the future with confidence and enthusiasm.

About Clearstone Central Laboratories: Clearstone Central Laboratories is a leading provider of clinical laboratory and centralized cardiac services to patients enrolled in clinical trials around the world. We employ 550 people at integrated facilities in Toronto, Paris, Hamburg, Beijing and Singapore. Clearstone owns and operates the leading edge central laboratory protocol manager system APOLLO CLPM(TM). Clearstone was formally the Global Central Laboratory unit of MDS Inc. For more information, visit our website at

SOURCE: Clearstone Central Laboratories

CONTACT: Caroline Keane, +1-905-206-8887, Ext. 4217,, or Lammert Albers, +44(0)1225-331-375,, both of Clearstone